What is STXS's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for STXS.

Stock Ratings / Health Care / STXS / options

NRXS (36) HYPR (38) VANI (28) OM (34) ⌘ Pro Terminal →

Stereotaxis Inc. (STXS) Options Positioning, Max Pain & Unusual Sweeps

$0.88 +2.03% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.88

Stereotaxis Inc. (STXS) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $86.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on STXS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is STXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Stereotaxis Inc. (NYSE: STXS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $0.88 (+2.03% 1D, market cap $86.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, STXS ranks #961 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does STXS compare to NRXS and HYPR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), STXS carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of 52.7%, and ROIC of -35.0%. By comparison, NRXS (Neuraxis Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $89.5M) and HYPR (Hyperfine Inc. (Class A)) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for STXS?

▼

Per STXS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001289340), Stereotaxis Inc. generated $32.4M in revenue (+20.3% YoY), -$21.6M in net income, and -$13.7M in free cash flow against $52.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.88 (+0.18%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STXS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (22/100 Composite)

🔍 WHY STXS SCORES 22/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (36% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52.7% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.06-5.7% Next Q

Q2 (-2Q)

Grade E$1.00+3% Next Q

Q3 (-1Q)

Grade E$1.03-14.6% Next Q

Current

Grade E$0.88-11.4% Hist 90D α

Trajectory: E (30) → E (22)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a STXS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While STXS currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.20) and Max Pain ($0.92) forces dealer call-delta covering toward $3.08.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $STXS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “STXS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 22%NO 78%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (STXS)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for STXS.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STXS)

✓Walkthrough of STXS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

STXS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.68%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.91H $0.91L $0.86C $0.88VOL 1.44M

RES: $1.12SUP: $0.80SMA50: $1.20SMA200: $1.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

STXS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 STXS Butterfly Map → + Track STXS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +20.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on STXS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for STXS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for STXS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STXS)

Health Care Rank #961 of 1015 ⚔️ NRXS vs STXS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (STXS vs. NRXS, HYPR, VANI, OM)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Stereotaxis Inc. (STXS) ranks #961 by composite RQD confidence (22/100, grade E) and #673 by equity capitalization ($86.4M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with STXS at 22/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
STXS ACTIVE Stereotaxis Inc.	E	22/100	—	52.7%	-35.0%	+2.03%	$86.4M	Benchmark Subject
NRXS Neuraxis Inc.	D-	36/100	—	84.2%	-35.0%	-7.43%	$89.5M	/nrxs-vs-stxs →
HYPR Hyperfine Inc. (Class A)	D-	38/100	—	49.8%	-35.0%	+0.99%	$76.1M	/hypr-vs-stxs →
VANI Vivani Medical Inc.	E	28/100	3.9x	—	-35.0%	0.00%	$98.3M	/vani-vs-stxs →
OM Outset Medical Inc.	E	34/100	—	39.1%	-28.0%	-0.25%	$75.8M	/om-vs-stxs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001289340 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Stereotaxis Inc. (STXS) reported GAAP revenue of $32.4M (+20.3% vs. FY2024 revenue of $26.9M , and +20.9% cumulative change since FY2023) , GAAP net income of -$21.6M, operating cash flow of -$13.7M, and free cash flow of -$13.7M (-61.1% YoY). On the balance sheet, STXS closed FY2025 with $52.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$32.4M	-$21.6M	-$13.7M	-$13.7M	$52.3M	—
FY2024 (FY)	2024-12-31	$26.9M	-$24.0M	-$8.5M	-$8.5M	$46.7M	—
FY2023 (FY)	2023-12-31	$26.8M	-$20.7M	-$9.1M	-$9.1M	—	—

3. STXS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is STXS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does STXS compare to NRXS and HYPR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for STXS?

Where is STXS trading relative to its 50-day, 200-day, and 52-week technical levels?

STXS last traded at $0.88 (+2.03% on volume of 532,674 shares), positioning the stock -26.67% below its 50-day simple moving average ($1.20) and -47.93% below its 200-day simple moving average ($1.69). Across its 52-week range of $0.81 to $2.93, STXS sits at the 3.3% percentile with a 14-day RSI of 27.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.99).

Direct Sub-Reports: STXS RQD Cockpit STXS 12M Forecast STXS Earnings & Move STXS Dividends & DRIP STXS Insiders & 13F STXS Whale Options STXS Profit Sankey STXS News & Why

ROARABLE RATING BRIEF • RQD 22/100 (E) ✓ SEC XBRL & RQD VERIFIED

STXS — Stereotaxis Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Stereotaxis Inc. (STXS) earns a live Roarable RQD composite score of 22/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.88 (+2.03% 1D, market capitalization $86.4M).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 52.7%, operating margin of -60.0%, and free cash flow yield of -15.01%.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (3/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Stereotaxis Inc. (STXS) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Its market capitalization is $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Stereotaxis Inc. (STXS) reported $32.4M in annual revenue (up from $26.9M in FY2024, +20.3% YoY) and -$21.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($26.8M revenue, -$20.7M net income) through FY2025, STXS scaled operating cash flow to -$13.7M and free cash flow to -$13.7M, backed by $52.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 22/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -15.01% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.81 – $2.93 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), STXS carries a macro regime beta of 1.00 and gross margin of 52.7%.

Key Question #1: Can STXS sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $32.4M and free cash flow of -$13.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is STXS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

STXS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Stereotaxis Inc. (STXS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to STXS Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 23h ago

Stereotaxis Stock Price Forecast. Should You Buy STXS?

StockInvest.us report covering Stereotaxis Inc. (STXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026

Yahoo Finance report covering Stereotaxis Inc. (STXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Latvia's first robotic heart-rhythm program has treated its first patients

Stock Titan report covering Stereotaxis Inc. (STXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Stereotaxis, Inc. (STXS) Seasonal returns chart

Yahoo Finance UK report covering Stereotaxis Inc. (STXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

Stereotaxis, Inc. Announces Pauls Stradin? Clinical University Hospital Installs Genesis Robotic Magnetic Navigation System

www.marketscreener.com report covering Stereotaxis Inc. (STXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com UK • 1d ago

Canon Medical, Stereotaxis partner on imaging and robotics By Investing.com

Investing.com UK report covering Stereotaxis Inc. (STXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Canon imaging will be offered alongside a robot designed for existing labs, with no construction.

Stock Titan report covering Stereotaxis Inc. (STXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

Canon Medical Systems USA, Inc. and Stereotaxis, Inc. Collaborate to Advance Robotic Electrophysiology

www.marketscreener.com report covering Stereotaxis Inc. (STXS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

STXS Bull vs. Bear Conversation Board — What's Your Call at $0.88?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STXS 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $1.03 (+19.8%)

📌 Pinned Debate

Revenue grew from $26.9M in FY 2024 to $32.4M in FY 2025 and reported cash rose to $13.4M, with a 0.5 Debt/Equity ratio and an Altman Z

Long STXS at $0.86 targeting $1.03. Revenue grew from $26.9M in FY 2024 to $32.4M in FY 2025 and reported cash rose to $13.4M, with a 0.5 Debt/Equity ratio and an Altman Z-Score of 2.5 supporting the balance sheet pillar.. Institutional whale score is 3/20 and the risk/reward vs. the $0.81 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 22/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.86 and keeping dry powder in case we test $0.80.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.71 (-17.4%)

Spot @ $0.86

ROIC of -35%, an FCF yield of -15.01%, and operating margin of -60% show the business is not generating cash returns, pulling the RQD s

I respect the product at Stereotaxis Inc., but the stock at $0.86 is a different story. ROIC of -35%, an FCF yield of -15.01%, and operating margin of -60% show the business is not generating cash returns, pulling the RQD score to 22 and grade E.. FCF yield is -15.01% and RQD sits at 22/100 (E) — why pay up here when you can wait for next quarter's numbers?